Companies

Summit Therapeutics

7 articles

Industry NewsSummit Therapeutics / AkesoBioSpace

FDA rejects Summit's ivonescimab in EGFR-mutated lung cancer, citing missing survival benefit

  • FDA issued a complete response letter for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy, which would have been the first US approval of a PD-1xVEGF bispecific.
  • The agency said progression-free survival gains without a statistically significant overall survival benefit do not show a positive benefit-risk profile; HARMONi missed its OS endpoint, and Summit's September follow-up analysis did not change that.
  • Summit says it will keep building evidence across several NSCLC settings and gave no next step for this indication; partner Akeso already markets the drug in China.
PointsBased on public reports

The rejection was widely expected, and the lesson is about trial design: a PFS-only win in a post-TKI setting will not clear today's FDA. The bigger pivot is the Western first-line HARMONi-3 readout, which now carries the whole US thesis, and the combination partners lined up with Summit (AstraZeneca, Pfizer, Revolution Medicines) are holding options, not commitments.

Industry NewsSummit Therapeutics / Capricor / Vertex PharmaceuticalsBioSpace

FDA's Crowded November: Ivonescimab, Deramiocel and Povetacicept Face Verdicts

  • Summit's ivonescimab for EGFR-mutated lung cancer after TKI therapy is due by November 14; it would be the first PD-1xVEGF bispecific cleared in the US. Capricor's DMD cell therapy deramiocel is due November 22 after a 9-3 negative advisory vote.
  • Vertex's povetacicept in IgA nephropathy is due by November 30; rivals from Novartis and Vera are already approved. At least 11 action dates fall this month.
PointsBased on public reports

Ivonescimab is the cleanest read-through: a progression-free-survival win without a significant overall-survival result at filing, so approval would show how much the FDA discounts a later nominal survival signal. Capricor is the opposite, a negative panel and a prior rejection. Povetacicept is a late entrant, so label and pricing decide how fast it takes share.

Industry NewsSummit TherapeuticsBioSpace

Pfizer, AstraZeneca, Revolution Medicines line up ivonescimab combos ahead of FDA decision

  • AstraZeneca will test ivonescimab with Datroway (TROP2 ADC, with Daiichi Sankyo) starting in first-line triple-negative breast cancer, and with CLDN18.2 ADC sone-ve in GI cancers; Pfizer plans pairings with its vedotin ADCs including Padcev.
  • Revolution Medicines offered its RAS(ON) inhibitors, among them zoldonrasib and elironrasib, as partners for RAS-mutant tumors; Summit says more collaborations are under discussion.
  • FDA is due to decide on ivonescimab in second-line non-squamous NSCLC on November 14; final HARMONi-3 progression-free survival data are expected before year-end.
  • Analysts at Mizuho and Stifel are bullish, while AstraZeneca notes most positive data are China-only.
PointsBased on public reports

Partners queuing for combo trials before any US approval is a bet that PD-1xVEGF becomes a backbone, and it gives Summit leverage beyond monotherapy sales. But each ADC pairing multiplies toxicity and dosing unknowns, and AstraZeneca's China-only caveat hints that a Western HARMONi-3 readout, not the November 14 decision, is the real test of the backbone thesis.

Industry NewsAkeso / Summit TherapeuticsEndpoints News

Akeso details ivonescimab's survival win in biliary tract cancer, a China-only trial

  • Akeso presented HARMONi-GI1 at ESMO 2026: its PD-1xVEGF bispecific ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line advanced biliary tract cancer.
  • The 682-patient study ran in China only and was sponsored and analyzed by Akeso; overall survival was the key result.
  • Summit Therapeutics holds rights outside China, and the data are already prompting Keytruda comparisons.
PointsBased on public reports

An overall-survival win over an anti-PD-1/L1 backbone is the claim PD-1xVEGF bispecifics need, and biliary cancer is a small, low-risk place to show it. But a China-only, Akeso-run trial will not settle Western regulators, so the value to Summit hinges on global trials such as its lung program, not on this readout.

Industry NewsSummit Therapeutics / AstraZeneca / Daiichi SankyoEndpoints News

Summit, AstraZeneca and Daiichi Sankyo to test ivonescimab plus Datroway, starting with Phase III in 1L TNBC

  • Summit, AstraZeneca and Daiichi Sankyo announced a clinical collaboration combining ivonescimab (PD-1xVEGF bispecific) with Datroway (datopotamab deruxtecan, a TROP2-directed ADC).
  • It starts with a Phase III study in first-line triple-negative breast cancer, with plans to expand to other settings including lung cancer.
  • The companies will share trial costs, and each retains development and commercial rights to its own drug.
PointsBased on public reports

Three companies, two assets, and no one gives up rights: this is a cost-sharing structure, not a licensing deal. For Summit, pairing ivonescimab with a validated TROP2 ADC borrows AstraZeneca and Daiichi's TNBC credibility and trial muscle. For the big partners, it is a cheap hedge on the PD-1xVEGF class. I would want to see the control arm and endpoints before judging how much it de-risks.

Industry NewsAstraZeneca / Summit TherapeuticsFierce Biotech

AstraZeneca Takes a $2B Stake in Summit to Pair Ivonescimab with Its ADCs

  • AstraZeneca is buying $2B of convertible preferred stock, giving it about 12% of Summit's common stock (about 10.6% fully diluted).
  • The first combination pairs Summit's PD-1xVEGF bispecific ivonescimab with AstraZeneca's CLDN18.2-directed ADC in gastrointestinal cancers; a memorandum of understanding covers a broader program with more AstraZeneca ADCs.
PointsBased on public reports

This is AstraZeneca buying a seat rather than a pipeline: equity plus combination rights instead of an acquisition or license, keeping it close to a PD-1xVEGF class it doesn't own without paying for the asset outright. The bet is that ADC plus PD-1xVEGF combinations become a next oncology backbone, with AstraZeneca's ADC portfolio as the partner of choice. The broader MOU is non-binding, so definitive terms are the thing to watch.

Industry NewsAkeso / Summit TherapeuticsEndpoints News

Ivonescimab Beats Keytruda on Survival in Phase 3 NSCLC Trial

  • Ivonescimab (Akeso/Summit's PD-1 x VEGF bispecific) reduced risk of death by 27% vs. Merck's Keytruda in the Phase 3 HARMONi-2 trial.
  • Trial enrolled treatment-naive, PD-L1-positive advanced NSCLC patients in China.
  • Median overall survival: 30.75 months for ivonescimab vs. 22.57 months for Keytruda.
  • Adds to the trial's earlier primary PFS win — a 49% reduction in progression/death risk (11.14 vs. 5.82 months).
  • Fourth Phase 3 ivonescimab readout to hit its OS endpoint, bolstering the case for combining PD-1 blockade with anti-VEGF activity in one bispecific.
  • Akeso (China) and Summit Therapeutics (ex-China licensee) are co-developing the drug as a head-to-head Keytruda challenger.
PointsBased on public reports

A head-to-head overall-survival win over Keytruda is about as rare an event as oncology drug development produces — Merck's franchise has fended off nearly every direct challenger for a decade, and ivonescimab is now four-for-four on OS across its Phase 3 program. That changes the calculus for Summit, whose ex-China license from Akeso looked speculative at signing and now looks like one of the shrewder biotech deals in recent memory — every data cut adds leverage for future pricing, partnering, or M&A conversations. It's also the clearest advertisement yet for the China-originated-asset licensing wave Western biotechs have been chasing: a domestically-developed bispecific outrunning the world's best-selling drug in its own trial. For Merck, it lands squarely as Keytruda nears patent cliff — this isn't a niche subtype win, it's a direct share threat in frontline NSCLC, the franchise's core indication.